KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.90

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.

Deniz Ece Kaya, Riley Cook, Simona Iacobelli, Giorgio Napolitani, Sila Gerlevik, Nogayhan Seymen, Flore Sicre de Fontbrune, Morag Griffin, Camilla Frieri, Constantijn J M Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Jean-Baptiste Méar, Marica Laurino, Beatrice Drexler, Etienne Daguindau, Marleen van Os, Sofie Terwel, Carlo Dufour, Mohammad M Karimi, Austin G Kulasekararaj, Regis Peffault De Latour, Antonio M Risitano, Ghulam Mufti

NEJM Evid 5(5) EVIDoa2500174

PMID42047558
PMCID-
DOI10.1056/EVIDoa2500174
发表日期2026-04-28
入排依据:The record describes a secondary analysis of clonal dynamics from a Phase 3 randomized trial, but does not report on a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required for eligibility.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: A Phase 3 randomized trial compared immunosuppressive therapy with or without eltrombopag in untreated patients with aplastic anemia (AA) and showed that addition of eltrombopag increased the rate, rapidity, and durability of hematological response, without increasing transformation to myeloid malignancies. We sought to systematically investigate clonal hematopoiesis (CH) dynamics from patient samples from this trial. METHODS: Peripheral blood and bone marrow aspirates were collected at diagnosis (i.e., baseline) and at 6 and 24 months from patients with severe or very severe AA. Genetic testing for somatic mutations was performed using 31-gene "core" and 291-gene "extended" custom targeted panels and analyzed longitudinally. RESULTS: Samples were collected from patients at baseline (n=170) and 6 (n=150) and 24 months (n=103); 85 patients' samples were tested at all three timepoints. Somatic mutations were present in 30% of patients at baseline, 55.3% at 6 months and 79.6% at 24 months, with a mean number of mutations per patient of 0.4, 1.2, and 2.5, at baseline and 6 and 24 months, respectively. CONCLUSIONS: CH was frequent in patients with AA and its prevalence appeared to be higher at posttherapy timepoints than at diagnosis. CH in AA may reflect the survival and expansion of selected residual hematopoietic stem/progenitor cells associated with immune-mediated damage. (Funded by Cancer Research UK, Bloodwise UK, and Novartis AG; ClinicalTrials.gov number, NCT02099747; EudraCT number, 2014-000363-40.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。